Plain English Summary
An FDA-approved GLP-1 receptor agonist used for both type 2 diabetes (Victoza) and weight loss (Saxenda). An earlier-generation option in the GLP-1 family, requiring daily injections versus weekly dosing of newer agents.
What People Use It For
Realistic Expectations
Best Case
5–8% body weight loss over 56 weeks in clinical trials (Saxenda).
Common Outcome
Moderate weight loss with manageable GI side effects; less potent than semaglutide.
Low / No Response
Minimal weight loss; GI side effects may limit adherence.
Side Effects & Risks
Common Side Effects
Warnings
- Contraindicated in personal/family history of medullary thyroid carcinoma or MEN2
- Pancreatitis risk
- Requires medical supervision and prescription
Who This Is Not For
People with thyroid cancer history, pancreatitis history, or severe GI conditions.
Commonly Confused With
Timeline of Expected Changes
Weight loss typically begins within 4–8 weeks; full effect at 6–12 months.
Researchers also explore
Semaglutide
Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes that has become one of the most effective weight loss medications available. It works by mimicking a natural hormone that regulates appetite and blood sugar, helping people feel full faster and longer.
Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist that has shown even stronger weight loss results than semaglutide in clinical trials. It targets two hormone pathways instead of one, making it potentially more effective for both weight loss and blood sugar control.
Retatrutide
Retatrutide is a triple hormone receptor agonist (GLP-1, GIP, and glucagon) in late-stage clinical trials showing the strongest weight loss results of any obesity drug to date—up to 24% body weight reduction in trials.
GIP (Glucose-dependent Insulinotropic Polypeptide)
GIP is an incretin hormone naturally secreted by the intestine in response to nutrient intake. It plays a critical role in regulating insulin secretion, fat metabolism, and systemic energy balance. While historically viewed primarily as an insulin-stimulating hormone, recent research—particularly involving dual GIP/GLP-1 receptor co-agonists like tirzepatide—highlights its significant role in weight management and metabolic health.
Researcher Sentiment
No votes yet — be the first
Educational Content Only
This is not medical advice. Always consult a licensed healthcare provider before using any compound. No dosing or sourcing guidance is provided.